thymosin beta-4 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-08. Numbers and descriptions here follow the published literature rather than marketing material.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
Lyophilized peptide powder is normally held desiccated at −20 °C, with −80 °C used for longer storage periods. Allowing a sealed vial to reach room temperature before opening is standard practice, because condensation forming on cold powder introduces moisture. Once dissolved, solutions are typically kept cold and shielded from light. Repeated freeze-thaw cycles are avoided because they encourage aggregation and gradual loss of material. These conventions are general to synthetic peptides rather than unique to any one sequence.
Purity and identity are separate measurements and are often confused. Reverse-phase high-performance liquid chromatography, usually with ultraviolet detection near 214 nanometres, reports the share of total peak area belonging to the target compound. Mass spectrometry by electrospray or matrix-assisted laser desorption then checks whether the observed mass matches the expected sequence. Neither measurement alone shows that a vial holds the intended peptide. Peptide content, meaning the fraction of vial mass that is genuine peptide rather than counter-ion, water or residual acid, is reported separately and is frequently lower than the stated purity figure.
The regulatory position is broadly consistent across major jurisdictions: no thymosin beta-4 fragment is an approved medicine, and laboratory material is commonly labelled as not intended for human consumption. Anti-doping rules in sport list thymosin beta-4 and its fragments among prohibited peptide hormones. Because these products travel through research-chemical channels rather than pharmaceutical supply chains, quality varies considerably between vendors. Independent testing of identity, purity and sterility is the only dependable check, and a certificate of analysis describes one batch rather than a supplier's whole catalogue.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilised powder | Sealed vial; reconstituted before laboratory use |
| Appearance | White to off-white solid | Visual descriptor used on certificates of analysis |
| Solubility class | Water-soluble | Dissolves in water and aqueous buffers |
| Reported mass, fragment | Near 889 Da | Value depends on the stated sequence |
| Reported mass, parent protein | Near 4963 Da | 43-residue thymosin beta-4 |
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.
TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.
Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.
No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.
Though this field of research is still ongoing, it has generated a wide amount of interest in the scientific community and is currently being investigated for a variety of biomedical applications in areas of tissue regeneration and repair.
==== Biomedical ==== The Biomedical Program at Bladensburg High School is a high school curriculum that focuses on medical and health careers, such as physicians and research doctors. Students who have a strong interest in pursuing a career in health-related fields have an opportunity to engage in biomedical research, internships, and practicums, and to enroll in medical-related science courses and other advanced placement courses. The curriculum introduces students to a wide variety of medical careers through field trips, speakers in the medical field, internships, accelerated courses, a wide variety of electives related to the biological and social sciences, and independent research. Locations:
They experience these feelings by repeated contact through the six sense-bases; feeling conditions craving; craving conditions clinging; clinging conditions becoming; becoming conditions birth; birth conditions aging and death, sorrow, lamentation, sadness and distress. Similarly, the Madhupiṇḍikasutta (MN 18) also contains the following passage:Eye consciousness arises dependent on the eye and sights. The meeting of the three is contact. Contact is a condition for feeling. What you feel, you perceive. What you perceive, you think about. What you think about, you proliferate (papañca). What you proliferate about is the source from which a person is beset by concepts of identity that emerge from the proliferation of perceptions. This occurs with respect to sights known by the eye in the past, future, and present. [The same process is then repeated with the other six sense bases.]The Mahānidānasutta (DN 15) and its Chinese parallels such as DA 13 describe a unique version which is dubbed the "looped version" by Bucknell (DN 14 also has a similar looped chain but it adds the six sense fields after name and form):Name and form are conditions for consciousness. Consciousness is a condition for name and form. Name and form are conditions for contact. Contact is a condition for feeling. Feeling is a condition for craving. Craving is a condition for grasping. Grasping is a condition for continued existence. Continued existence is a condition for rebirth. Rebirth is a condition for old age and death, sorrow, lamentation, pain, sadness, and distress to come to be.
Sources: en.wikipedia.org
After a period of rest and recovery, Zita found herself regularly going back to Europe for the weddings of her children. She decided to move back to the continent full-time in 1952 to Luxembourg to look after her aging mother. Maria Antonia died at the age of 96 in 1959. The bishop of Chur proposed to Zita that she move into a residence that he administered (formerly a castle of the Counts de Salis) at Zizers, Graubünden in Switzerland. As the castle had enough space for visits from her large family and a nearby chapel (a necessity for the devoutly-Catholic Zita), she accepted with ease. Zita occupied herself in her final years with her family. Although the restrictions on the Habsburgs entering Austria had been lifted, that applied only to those born after 10 April 1919. That meant that Zita could not attend the funeral of her daughter Adelheid in 1971, which was painful for her. She also involved herself in the efforts to have her deceased husband, the "Peace Emperor" canonised. In 1982, the restrictions were eased, and she returned to Austria after being absent for six decades. Over the next few years, the Empress made several visits to her former Austrian homeland and even appeared on Austrian television. In a series of interviews with the Viennese tabloid newspaper Kronen Zeitung, Zita expressed her belief that the deaths of Crown Prince Rudolf of Austria and his mistress Baroness Mary Vetsera, at Mayerling, in 1889, were not a double suicide but rather murder by French or Austrian agents.
=== Meteorology and physics === GR, METAR reporting code for hail ≥ 5 mm in diameter Gutenberg–Richter law, in seismology Grashof number, in fluid dynamics General relativity, Einstein's 1915 theory of gravity
== Self-resistance == Tabtoxin resistance protein (TTR) is an enzyme that catalyzes the acetylation of TBL, rendering tabtoxin-producing pathogens tolerant to their own phytotoxins. The structure of an inactivated mutant of TTR is solved with its natural cofactor acetyl-CoA to 1.55 Å resolution. The binary complex forms a characteristic V-shape for substrate binding and contains the four motifs conserved in the GCN5-related N-acetyltransferase (GNAT) superfamily, which also includes the histone acetyltransferases (HATs). There are reports that TTR possesses HAT activity and suggest an evolutionary relationship between TTR and other GNAT members. The production of tabtoxin itself is also part of the self-resistance strategy. These pathogens produce TBL before tabtoxin is produced; to detoxify, the enzyme TblF links TBL to threonine (Thr), producing a non-toxic product.
=== Act 2 === Lucinda, a runaway slave, rifles through the pockets of the dead chain gang prisoners. Inman regains consciousness and awakens, which startles her. Lucinda frees Inman, who resumes his journey. Back at Black Cove Farm, Stobrod and his traveling companion Pangle still rely upon Ruby and Ada for sustenance. Stobrod tries to convince Ruby that he is a changed man, but Ruby remains skeptical. Inman meets Sara, a war widow, who is trying to comfort her baby. Inman helps her, gains her trust, and is invited to spend the night. At Black Cove Farm, Teague appears, with a copy of the newspaper that lists the names of deserters, on which Ruby sees her father's name. The next morning, Inman and Sara react quickly when Union soldiers appear. At a campfire in the woods, Teague and his men confront Stobrod and Pangle, shoot them and leave them for dead. Ada finds the two men, and expresses compassion for Stobrod ("I feel sorry for you"). Ada later goes hunting in the woods. There, she and Inman reunite. The other characters whom Inman has encountered on his odyssey appear to Inman, and urge him to tell Ada about his adventures ("Tell her of the slave you met"; "Tell her how the boat went down"). The couple affirms their pledge to each other. Teague continues his pursuit. Ada and Inman consummate their love, on their final night together. Eventually, Teague and the Home Guard track down Inman. In the final battle, Inman is killed.
Sources: en.wikipedia.org
No. TB-500 is a trade-style label used for a synthetic peptide described as a fragment of thymosin beta-4, while thymosin beta-4 is the full 43-residue protein. The two differ in size and are not interchangeable terms in analytical work.
Naming for research peptides is not standardised, and suppliers sometimes apply the same label to different chain lengths. Certificates of analysis and mass data are the practical way to determine what a given lot contains.
The fragment commonly cited under this label is reported near 889 Da, and the parent protein near 4963 Da. Reported values shift with the exact sequence and with residual counter-ions or water in the sample.
Desiccated storage at −20 °C is conventional, with −80 °C for extended periods. Vials should be warmed to room temperature before opening to prevent condensation on the powder.